Inatherys sas
WebDec 31, 2024 · SAS, société par actions simplifiée Registered Address 4 RUE PIERRE FONTAINE, CAMPUS 1, 91058 EVRY CEDEX, EVRY-COURCOURONNES 91000, France … WebInatherys is a biotechnology company developing monoclonal antibodies. It is engaged in the design and development of molecules providing solutions for the treatment of …
Inatherys sas
Did you know?
WebFeb 28, 2024 · Originator Inatherys Class Monoclonal antibodies Mechanism of Action Undefined mechanism Orphan Drug Status No New Molecular Entity Yes Highest … WebBefore working in industry, Jean- Jacques practised medicine at the Claude Bernard Hospital in Paris, France after gaining his medical degree at the University of Paris. He is a Non- Executive Director at MedDay SAS, Inatherys SAS and Polyphor Limited and Chairman of the Inserm Transfert Initiatives Investment Committee.
Web- Options to Shares of Inatherys SAS (unvalued as private and not vested) - Options to Shares of STEP Pharma SAS (unvalued as private and not vested) - 13Ό00 Shares of ObsEva SA (valued at ca. 50Ό00 USD) - 17Ό00 Options to Shares of ObsEva SA (valued at 0 USD currently) - 588 Shares of ROCHE Holdings (valued at ca. 180Ό00 CHF) WebMar 1, 2024 · INA-03 is under clinical development by Inatherys and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for …
WebInatherys is a biotechnology company developping monoclonal antibodies for the treatment of cancers and inflammatory diseases. Fontaine, Bourgogne, France 1-10 Private … WebJean- Jacques practised medicine at the Claude Bernard Hospital in Paris, France after gaining his medical degree at the University of Paris. He is a Non- Executive Director at MedDay SAS, Inatherys SAS and Polyphor Limited and Chairman of the Inserm Transfert Initiatives Investment Committee.
WebFounded in 2009 Private Company "Inatherys is a biotechnology company developing monoclonal antibodies for therapies for cancers and severe inflammatory diseases resistant to conventional treatment. INA03 and new generations of antibodies are targeting the transferrin receptor (CD71). CD71 regulates cellular activation and proliferation.
WebHe is a co-founder of a start-up, INATHERYS SAS, that develops therapeutic monoclonal antibodies for treatment of cancer and inflammatory … d2 4 socket scytheWebWorking at Inatherys Glassdoor See what employees say it's like to work at Inatherys. Salaries, reviews, and more - all posted by employees working at Inatherys. Sign In … d24 tablet white oblongWebApr 28, 2024 · IP authentication when working within your organization’s network. Login with a username/password associated to your organization’s account. Persisted access using … d24 light with bluetooth controller